333 related articles for article (PubMed ID: 25801024)
1. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
Najjar M; Suebsuwong C; Ray SS; Thapa RJ; Maki JL; Nogusa S; Shah S; Saleh D; Gough PJ; Bertin J; Yuan J; Balachandran S; Cuny GD; Degterev A
Cell Rep; 2015 Mar; 10(11):1850-60. PubMed ID: 25801024
[TBL] [Abstract][Full Text] [Related]
2. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.
Fauster A; Rebsamen M; Huber KV; Bigenzahn JW; Stukalov A; Lardeau CH; Scorzoni S; Bruckner M; Gridling M; Parapatics K; Colinge J; Bennett KL; Kubicek S; Krautwald S; Linkermann A; Superti-Furga G
Cell Death Dis; 2015 May; 6(5):e1767. PubMed ID: 25996294
[TBL] [Abstract][Full Text] [Related]
3. Sibiriline, a new small chemical inhibitor of receptor-interacting protein kinase 1, prevents immune-dependent hepatitis.
Le Cann F; Delehouzé C; Leverrier-Penna S; Filliol A; Comte A; Delalande O; Desban N; Baratte B; Gallais I; Piquet-Pellorce C; Faurez F; Bonnet M; Mettey Y; Goekjian P; Samson M; Vandenabeele P; Bach S; Dimanche-Boitrel MT
FEBS J; 2017 Sep; 284(18):3050-3068. PubMed ID: 28715128
[TBL] [Abstract][Full Text] [Related]
4. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis.
Kearney CJ; Cullen SP; Clancy D; Martin SJ
FEBS J; 2014 Nov; 281(21):4921-34. PubMed ID: 25195660
[TBL] [Abstract][Full Text] [Related]
5. The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
Qin X; Hu L; Shi SN; Chen X; Zhuang C; Zhang W; Jitkaew S; Pang X; Yu J; Tan YX; Wang HY; Cai Z
Biochem Pharmacol; 2020 Jul; 177():113947. PubMed ID: 32247850
[TBL] [Abstract][Full Text] [Related]
6. Identification of the Raf kinase inhibitor TAK-632 and its analogues as potent inhibitors of necroptosis by targeting RIPK1 and RIPK3.
Chen X; Zhuang C; Ren Y; Zhang H; Qin X; Hu L; Fu J; Miao Z; Chai Y; Liu ZG; Zhang H; Cai Z; Wang HY
Br J Pharmacol; 2019 Jun; 176(12):2095-2108. PubMed ID: 30825190
[TBL] [Abstract][Full Text] [Related]
7. Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
Li Y; Xiong Y; Zhang G; Zhang L; Yang W; Yang J; Huang L; Qiao Z; Miao Z; Lin G; Sun Q; Niu T; Chen L; Niu D; Li L; Yang S
J Med Chem; 2018 Dec; 61(24):11398-11414. PubMed ID: 30480444
[TBL] [Abstract][Full Text] [Related]
8. Critical contribution of oxidative stress to TNFα-induced necroptosis downstream of RIPK1 activation.
Shindo R; Kakehashi H; Okumura K; Kumagai Y; Nakano H
Biochem Biophys Res Commun; 2013 Jun; 436(2):212-6. PubMed ID: 23727581
[TBL] [Abstract][Full Text] [Related]
9.
Zhang H; Xu L; Qin X; Chen X; Cong H; Hu L; Chen L; Miao Z; Zhang W; Cai Z; Zhuang C
J Med Chem; 2019 Jul; 62(14):6665-6681. PubMed ID: 31095385
[TBL] [Abstract][Full Text] [Related]
10. RIPK1 inhibitor Cpd-71 attenuates renal dysfunction in cisplatin-treated mice via attenuating necroptosis, inflammation and oxidative stress.
Wang JN; Liu MM; Wang F; Wei B; Yang Q; Cai YT; Chen X; Liu XQ; Jiang L; Li C; Hu XW; Yu JT; Ma TT; Jin J; Wu YG; Li J; Meng XM
Clin Sci (Lond); 2019 Jul; 133(14):1609-1627. PubMed ID: 31315969
[TBL] [Abstract][Full Text] [Related]
11. Ring closure strategy leads to potent RIPK3 inhibitors.
Wu S; Xu C; Xia K; Lin Y; Tian S; Ma H; Ji Y; Zhu F; He S; Zhang X
Eur J Med Chem; 2021 May; 217():113327. PubMed ID: 33730678
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.
Liu Y; Peng X; Guan X; Lu D; Xi Y; Jin S; Chen H; Zeng L; Ai J; Geng M; Hu Y
Eur J Med Chem; 2017 Jan; 126():122-132. PubMed ID: 27750146
[TBL] [Abstract][Full Text] [Related]
13. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis.
Newton K; Dugger DL; Wickliffe KE; Kapoor N; de Almagro MC; Vucic D; Komuves L; Ferrando RE; French DM; Webster J; Roose-Girma M; Warming S; Dixit VM
Science; 2014 Mar; 343(6177):1357-60. PubMed ID: 24557836
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity.
Li Z; Hao Y; Yang C; Yang Q; Wu S; Ma H; Tian S; Lu H; Wang J; Yang T; He S; Zhang X
Eur J Med Chem; 2022 Jan; 228():114036. PubMed ID: 34906762
[TBL] [Abstract][Full Text] [Related]
15. 24(S)-Hydroxycholesterol induces RIPK1-dependent but MLKL-independent cell death in the absence of caspase-8.
Vo DK; Urano Y; Takabe W; Saito Y; Noguchi N
Steroids; 2015 Jul; 99(Pt B):230-7. PubMed ID: 25697054
[TBL] [Abstract][Full Text] [Related]
16. Ensembling and filtering: an effective and rapid in silico multitarget drug-design strategy to identify RIPK1 and RIPK3 inhibitors.
Fayaz SM; Rajanikant GK
J Mol Model; 2015 Dec; 21(12):314. PubMed ID: 26589407
[TBL] [Abstract][Full Text] [Related]
17. RIPK1 and RIPK3: critical regulators of inflammation and cell death.
Newton K
Trends Cell Biol; 2015 Jun; 25(6):347-53. PubMed ID: 25662614
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
Biochem Biophys Res Commun; 2013 Jun; 435(3):506-11. PubMed ID: 23684619
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.
Canning P; Ruan Q; Schwerd T; Hrdinka M; Maki JL; Saleh D; Suebsuwong C; Ray S; Brennan PE; Cuny GD; Uhlig HH; Gyrd-Hansen M; Degterev A; Bullock AN
Chem Biol; 2015 Sep; 22(9):1174-84. PubMed ID: 26320862
[TBL] [Abstract][Full Text] [Related]
20. Structural study of ponatinib in inhibiting SRC kinase.
Guo M; Duan Y; Dai S; Li J; Chen X; Qu L; Chen Z; Wei H; Jiang L; Chen Y
Biochem Biophys Res Commun; 2022 Apr; 598():15-19. PubMed ID: 35151199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
